5FU: Clinical Trials

27 trials of 5FU, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 9 active not recruiting, 5 recruiting, 1 terminated. 27 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 327Completed 11, Active not recruiting 9, Recruiting 5, Terminated 1, Withdrawn 1
Phase 21Active not recruiting 1

Follow 5FU: new trials by email Literature Review of 5FU trials Research Report on 5FU

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial
Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma
Phase 3RecruitingCity of Hope Medical Center1292027-01-042026-11-05
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 3RecruitingSWOG Cancer Research Network942026-05-132026-05-22
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Biospecimen Collection, Cisplatin, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Phase 3RecruitingNRG Oncology4862025-10-072026-10-23
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
Phase 3RecruitingNRG Oncology3562025-08-212026-08-25
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Bevacizumab, Capecitabine, Cetuximab - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver
Phase 3RecruitingECOG-ACRIN Cancer Research Group4082024-04-102026-09-24
Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Carboplatin, Cisplatin, Computed Tomography - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma
Phase 3Active not recruitingECOG-ACRIN Cancer Research Group2902023-06-082026-09-14
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
Pembrolizumab, Placebo, Cisplatin - Gastric Cancer, Gastroesophageal Junction Cancer
Phase 3CompletedMerck Sharp & Dohme LLC1202020-07-292026-03-06
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
Capecitabine, Fluorouracil, Leucovorin - Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8
Phase 3Active not recruitingECOG-ACRIN Cancer Research Group3142020-05-262026-10-19
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Biospecimen Collection, Capecitabine, Carboplatin - Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
Phase 3Active not recruitingNRG Oncology3002019-06-262026-08-24
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
Atezolizumab, Biopsy of Bladder, Cisplatin - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma
Phase 3Active not recruitingNational Cancer Institute (NCI)4752019-06-032026-11-12
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
Pembrolizumab, Cisplatin, 5-fluorouracil - Stomach Neoplasms
Phase 3CompletedMerck Sharp & Dohme LLC15792018-11-082026-02-27
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension
Pembrolizumab, Cisplatin, 5-fluorouracil - Stomach Neoplasms
Phase 3WithdrawnMerck Sharp & Dohme LLC2018-11-082021-12-16
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
FUDR, Oxaliplatin, Leucovorin - Colorectal Cancer, Liver Metastases
Phase 3TerminatedSun Yat-sen University922018-05-282024-01-22
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Biospecimen Collection, Carboplatin, Cisplatin - Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm
Phase 3Active not recruitingChildren's Oncology Group5372018-05-242026-09-14
Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study
Atezolizumab, Bevacizumab, Biospecimen Collection - Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Phase 3Active not recruitingNational Cancer Institute (NCI)1202018-01-192026-11-12
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Atezolizumab, Biospecimen Collection, Computed Tomography - Colon Adenocarcinoma, DNA Repair Disorder
Phase 3Active not recruitingNational Cancer Institute (NCI)7122017-10-162026-11-13
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Pembrolizumab, Placebo, Cisplatin - Gastric Cancer, Gastroesophageal Junction Cancer
Phase 3CompletedMerck Sharp & Dohme LLC10072017-10-092026-03-09
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Bone Scan, Cisplatin, Clinical Observation - EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7
Phase 2 / Phase 3Active not recruitingNRG Oncology9242014-07-012026-11-12
Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer
Oxaliplatin, Irinotecan, Leucovorin - Pancreatic Cancer
Phase 3CompletedStanford University272013-08-142022-10-28
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Capecitabine - Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Phase 3CompletedNational Cancer Institute (NCI)5462010-04-052026-02-23

Showing 20 of 27. Sign in to see all of them.

Conditions studied

Colorectal Neoplasms (6)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (4)  ·  Stomach Neoplasms (4)  ·  Colonic Neoplasms (3)  ·  Pancreatic Neoplasms (3)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Urinary Bladder Neoplasms (2)  ·  Adenocarcinoma Of Esophagus (1)  ·  Appendiceal Neoplasms (1)  ·  Carcinoma (1)  ·  Colorectal Neoplasms, Hereditary Nonpolyposis (1)  ·  DNA Repair-Deficiency Disorders (1)  ·  Epstein-Barr Virus Infections (1)  ·  Fibrolamellar hepatocellular carcinoma (1)  ·  Hepatoblastoma (1)

Sponsors

National Cancer Institute (NCI) (8)  ·  Merck Sharp & Dohme LLC (4)  ·  NRG Oncology (4)  ·  ECOG-ACRIN Cancer Research Group (3)  ·  Children's Oncology Group (2)  ·  City of Hope Medical Center (1)  ·  Gruppo Oncologico del Nord-Ovest (1)  ·  SWOG Cancer Research Network (1)  ·  Stanford University (1)  ·  Sun Yat-sen University (1)  ·  US Oncology Research (1)

Countries

United States (23)  ·  Canada (11)  ·  China (6)  ·  Puerto Rico (6)  ·  Australia (5)  ·  Brazil (3)  ·  Germany (3)  ·  Israel (3)  ·  Italy (3)  ·  Japan (3)  ·  South Africa (3)  ·  Taiwan (3)  ·  Belgium (2)  ·  Chile (2)  ·  France (2)

Top investigators

Al B Benson (1)  ·  Alfredo Falcone, MD (1)  ·  Allen Cohn, MD (1)  ·  Carlos Rodriguez-Galindo (1)  ·  Carmen J Allegra (1)  ·  Daniel T Chang (1)  ·  David J Sher (1)  ·  Frank A Sinicrope (1)  ·  Gregory M Tiao (1)  ·  Howard M Katzenstein (1)  ·  Leonard Saltz, M.D. (1)  ·  Michael Lidsky (1)

Results publications

PMID 21997132, PMID 23233715, PMID 26861604, PMID 28006055, PMID 30777447, PMID 30975630, PMID 31268130, PMID 31553639, PMID 31618129, PMID 31657981, PMID 31811950, PMID 33356421, PMID 33370024, PMID 33975465, PMID 34874751, PMID 35602670, PMID 35623069, PMID 37073741, PMID 37222189, PMID 37598723, PMID 37875143, PMID 38131628, PMID 38134948, PMID 38315963, PMID 39644535, PMID 39938471, PMID 40025394, PMID 40750941, PMID 40829093, PMID 40953502, PMID 41005671, PMID 41880612, PMID 41964430, PMID 42456089, PMID 42525921

NIH funding

U10CA180868 (6), U10CA180820 (5), U10CA180886 (3), 2018 (2), 2023 (2), U10CA021115 (2), U10CA021661 (2), U10CA098543 (2), U10CA180888 (2), P30CA033572 (1), U10CA012027 (1), U10CA180821 (1), U10CA180822 (1), U10CA180830 (1)